When used in adjunction with ongoing statin therapy, the thyroid hormone analogue, eprotirome, led to a further significant, dose-dependent reduction of LDL-C levels by 22–32% from baseline.
Clin Lipidology. 2010;5(4):477-480. Eprotirome is a liver and thyroid hormone receptor-b-selective thyromimetic compound. In patients receiving statin therapy, eprotirome led to a further 22–32% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback